Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Videos|December 8, 2024
Dr Siegel on the Preliminary Use of Mezigdomide in Relapsed/Refractory Myeloma
Author(s)David M. Siegel, MD, PhD
David Samuel Dicapua Siegel, MD, discusses preliminary findings from the phase 1/2 CA057-003 trial of mezigdomide in relapsed/refractory multiple myeloma.
Advertisement
David Samuel Dicapua Siegel, MD, chief, Division of Multiple Myeloma, John Theurer Cancer Center, Hackensack University Medical Center, discusses preliminary findings from the phase 1/2 CA057-003 trial (NCT05372354) evaluating the novel agent mezigdomide for patients with relapsed or refractory multiple myeloma.
Advertisement
Related to this article
A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
2
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
3
Daraxonrasib Yields Durable Responses in Previously Treated RAS-Mutant NSCLC
4
Sonrotoclax Approval Generates New Options and Possibilities for R/R MCL
5